[go: up one dir, main page]

CA2115943A1 - Novel process for the preparation of cetrorelix lyophilisate - Google Patents

Novel process for the preparation of cetrorelix lyophilisate

Info

Publication number
CA2115943A1
CA2115943A1 CA002115943A CA2115943A CA2115943A1 CA 2115943 A1 CA2115943 A1 CA 2115943A1 CA 002115943 A CA002115943 A CA 002115943A CA 2115943 A CA2115943 A CA 2115943A CA 2115943 A1 CA2115943 A1 CA 2115943A1
Authority
CA
Canada
Prior art keywords
lyophilisate
preparation
peptide
novel process
cetrorelix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002115943A
Other languages
French (fr)
Other versions
CA2115943C (en
Inventor
Jurgen Engel
Burkhard Wichert
Dieter Sauerbier
Thomas Reissmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentaris IVF GmbH
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6480924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2115943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Publication of CA2115943A1 publication Critical patent/CA2115943A1/en
Application granted granted Critical
Publication of CA2115943C publication Critical patent/CA2115943C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A novel lyophilisate and method of preparation as well as the use of the lyophilisate to treat female infertility and for gonad protection. A lyophilisate of a peptide with 3 - 15 amino acids and optionally one or several bulking agents is prepared by dissolving 1 part by weight of peptide in 100 - 10,000 parts by weight of acetic acid and then transferring to water, the solution so obtained being lyophilized. Cetrorelix is preferred as the peptide.
CA002115943A 1993-02-19 1994-02-18 Novel process for the preparation of cetrorelix lyophilisate Expired - Lifetime CA2115943C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4305225.8 1993-02-19
DE4305225A DE4305225A1 (en) 1993-02-19 1993-02-19 New manufacturing process for Cetrorelix lyophilisate

Publications (2)

Publication Number Publication Date
CA2115943A1 true CA2115943A1 (en) 1994-08-20
CA2115943C CA2115943C (en) 2003-08-05

Family

ID=6480924

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002115943A Expired - Lifetime CA2115943C (en) 1993-02-19 1994-02-18 Novel process for the preparation of cetrorelix lyophilisate

Country Status (29)

Country Link
EP (2) EP0611572B1 (en)
JP (1) JP4033919B2 (en)
KR (2) KR100355686B1 (en)
CN (1) CN1109557C (en)
AT (1) ATE193653T1 (en)
AU (1) AU671881C (en)
BR (1) BR9400617A (en)
CA (1) CA2115943C (en)
CZ (2) CZ285768B6 (en)
DE (2) DE4305225A1 (en)
DK (1) DK0611572T3 (en)
ES (1) ES2148247T3 (en)
FI (1) FI110059B (en)
GR (1) GR3034237T3 (en)
HR (1) HRP940117B1 (en)
HU (1) HU218281B (en)
IL (1) IL108704A (en)
MX (1) MX9401312A (en)
NO (1) NO316601B1 (en)
NZ (2) NZ314707A (en)
PL (1) PL177177B1 (en)
PT (1) PT611572E (en)
RU (1) RU2145234C1 (en)
SG (1) SG46632A1 (en)
SI (1) SI9400087B (en)
SK (2) SK283021B6 (en)
TW (1) TW387812B (en)
UA (1) UA43829C2 (en)
ZA (1) ZA941136B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319192B1 (en) 1998-04-23 2001-11-20 Zentaris Ag Method for the treatment of fertility disorders
US7696149B2 (en) 2000-05-18 2010-04-13 Aeterna Zentaris Gmbh Pharmaceutical administration form for peptides, process for its preparation, and use
WO2012077131A1 (en) 2010-12-06 2012-06-14 Astron Research Limited A stable ready-to-use cetrorelix injection
WO2020254952A1 (en) 2019-06-17 2020-12-24 Intas Pharmaceuticals Ltd. A stable formulation of cetrorelix

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
PE63998A1 (en) * 1996-04-19 1998-10-30 Merck & Co Inc ANTI-FUNGOUS COMPOSITIONS
DE19712718C2 (en) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilized and activity-stabilized complexes of LHRH antagonists and process for their preparation
DE10040700A1 (en) * 2000-08-17 2002-02-28 Asta Medica Ag Salts of biologically active peptides, their production and use
DE10157628A1 (en) * 2001-11-26 2003-06-12 Zentaris Ag Solution for injection of an LHRH antagonist
US20030186892A1 (en) * 2002-03-28 2003-10-02 Rajneesh Taneja Enhancement of endogenous gonadotropin production
RS52966B (en) 2002-09-27 2014-02-28 Zentaris Gmbh FORM OF THE THERAPEUTIC APPLICATION OF ACTIVE PEPTIDES WITH THE LONG TERM RELEASE OF THE ACTIVE INGREDIENT
DE602005004014T2 (en) 2004-03-12 2008-12-11 Intercell Ag PROCESS FOR SOLUBILIZING PEPTIDE MIXTURES
EP1674082A1 (en) * 2004-12-22 2006-06-28 Zentaris GmbH Process for the manufacture of sterile suspensions or lyophilisates of low-soluble basic peptide complexes, pharmaceutical formulations comprising these complexes and their use as medicament
TWI442932B (en) * 2008-02-11 2014-07-01 Ferring Int Ct Sa Method for treating prostate cancer with GnRH antagonist
CN101629758B (en) * 2008-07-19 2012-09-26 浙江家泰电器制造有限公司 Liquid heating ware overheating protection controller assembly
CN101630607B (en) * 2008-07-19 2012-04-25 浙江家泰电器制造有限公司 Liquid heating ware overheating protection controller assembly
RU2454221C2 (en) * 2010-07-06 2012-06-27 Общество с ограниченной ответственностью "Завод Медсинтез" Method for preparing lyophilised antiviral agent
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
CN102423484B (en) * 2011-11-23 2014-01-15 深圳翰宇药业股份有限公司 Stable cetrorelix medicinal composition and preparation method thereof
EP3015553A1 (en) 2014-10-30 2016-05-04 Biotecon Diagnostics GmbH Stabilised reaction mixture
RU2667128C2 (en) * 2016-12-29 2018-09-14 Герман Петрович Беккер Composition for preparation of anti-tumor medication and method for preparation of anti-tumor medication based on it
CN112717119B (en) * 2021-01-27 2024-04-30 南京羚诺生物医药技术研究院有限公司 Cetrorelix pharmaceutical composition and preparation method thereof
JP2024522892A (en) 2021-06-25 2024-06-21 エクストロヴィス・アーゲー Pharmaceutical Compositions
CN114159544A (en) * 2022-01-24 2022-03-11 福州华为医药技术开发有限公司 Cetrorelix acetate for injection and preparation method thereof
CN115969954A (en) * 2023-01-09 2023-04-18 开封明仁药业有限公司 A kind of cetrorelix freeze-dried pharmaceutical composition for injection and preparation method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816386A (en) * 1972-06-20 1974-06-11 Abbott Lab Purification process for gn-rh
DD141996A1 (en) * 1979-02-21 1980-06-04 Ingrid Wolf METHOD FOR PRODUCING LYOPHILIZED LHRH PRAEPARATIONS
CS230614B1 (en) * 1982-08-06 1984-08-13 Martin Cs Flegel Analogues of realising factor for luteining and folliculstimulated hormon
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
EP0268066A3 (en) * 1986-10-17 1990-07-11 Syntex (U.S.A.) Inc. Fertility control and uterine therapy in dogs with luteinizing hormone releasing hormone antagonists
DE3735614A1 (en) * 1986-10-31 1988-07-28 Asta Pharma Ag Ifosfamide lyophilisate and process for its preparation
DK49987A (en) * 1987-01-30 1988-07-31 Nordisk Gentofte PROCEDURE FOR TREATING INFERTILITY AND METHOD FOR USING THE PROCEDURE
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
FR2635006B1 (en) * 1988-08-02 1990-10-19 Letourneur Bernard MEDICINE FOR REGULATING HORMONAL SECRETIONS AND TREATING STERILITY
US5180711A (en) * 1990-06-14 1993-01-19 Applied Research Systems Ars Holding N.V. Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
CN1036343C (en) * 1990-11-10 1997-11-05 天津市计划生育研究所 Preparation method of novel luteinizing hormone-releasing hormone antagonistic analog

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319192B1 (en) 1998-04-23 2001-11-20 Zentaris Ag Method for the treatment of fertility disorders
US7696149B2 (en) 2000-05-18 2010-04-13 Aeterna Zentaris Gmbh Pharmaceutical administration form for peptides, process for its preparation, and use
US7718599B2 (en) * 2000-05-18 2010-05-18 Aeterna Zentaris Gmbh Pharmaceutical administration form for peptides, process for its preparation, and use
WO2012077131A1 (en) 2010-12-06 2012-06-14 Astron Research Limited A stable ready-to-use cetrorelix injection
WO2020254952A1 (en) 2019-06-17 2020-12-24 Intas Pharmaceuticals Ltd. A stable formulation of cetrorelix

Also Published As

Publication number Publication date
TW387812B (en) 2000-04-21
IL108704A (en) 2005-05-17
SI9400087A (en) 1994-12-31
UA43829C2 (en) 2002-01-15
NO316601B1 (en) 2004-03-08
DE4305225A1 (en) 1994-08-25
NO940564L (en) 1994-08-22
KR100372187B1 (en) 2003-02-14
JP4033919B2 (en) 2008-01-16
EP0947200A3 (en) 2004-03-24
MX9401312A (en) 1994-08-31
PT611572E (en) 2000-11-30
HRP940117B1 (en) 2001-02-28
IL108704A0 (en) 1994-05-30
CN1112019A (en) 1995-11-22
FI110059B (en) 2002-11-29
NO940564D0 (en) 1994-02-18
SK283022B6 (en) 2003-02-04
HU218281B (en) 2000-07-28
CZ284314B6 (en) 1998-10-14
SI9400087B (en) 2002-02-28
KR100355686B1 (en) 2002-12-11
AU671881B2 (en) 1996-09-12
EP0947200A2 (en) 1999-10-06
SK19594A3 (en) 1994-09-07
NZ250906A (en) 1997-07-27
AU5523594A (en) 1994-08-25
CZ285768B6 (en) 1999-11-17
JPH06271476A (en) 1994-09-27
HU9400481D0 (en) 1994-12-28
HRP940117A2 (en) 1996-08-31
ZA941136B (en) 1994-08-29
EP0611572A3 (en) 1995-01-11
EP0611572B1 (en) 2000-06-07
FI940779L (en) 1994-08-20
CZ31294A3 (en) 1994-09-14
EP0611572A2 (en) 1994-08-24
EP0947200B1 (en) 2015-03-11
PL177177B1 (en) 1999-10-29
DK0611572T3 (en) 2000-09-25
BR9400617A (en) 1994-09-27
NZ314707A (en) 1999-02-25
ES2148247T3 (en) 2000-10-16
HUT67117A (en) 1995-02-28
GR3034237T3 (en) 2000-12-29
CA2115943C (en) 2003-08-05
SG46632A1 (en) 1998-02-20
ATE193653T1 (en) 2000-06-15
AU671881C (en) 2004-01-15
SK283021B6 (en) 2003-02-04
FI940779A0 (en) 1994-02-18
DE59409389D1 (en) 2000-07-13
RU2145234C1 (en) 2000-02-10
CN1109557C (en) 2003-05-28

Similar Documents

Publication Publication Date Title
CA2115943A1 (en) Novel process for the preparation of cetrorelix lyophilisate
RU94005001A (en) PEPTIDE BASED LYOPHYLIZATE
JPS6434923A (en) Aerosolization of proteinaceous remedy
IE800694L (en) Enzymatic producion of peptides.
CA2194660A1 (en) Growth differentiation factor-11
DE3823590A1 (en) LHRH ANTAGONISTS, THEIR PRODUCTION AND RELATED PHARMACEUTICAL PREPARATIONS
AU4868590A (en) Method of fastening hose to nipple and hose connection obtained by such method
ES8704973A1 (en) Peptides selected from amino-acid residues 11 to 23 of VIP.
CA2057860A1 (en) Immunoactive peptides and antibodies and their use in anti-allergy treatment
CA2248710A1 (en) Conotoxin peptide pviia
CA2053288A1 (en) Expression of human apolipoproteins ai and ai-milano in yeast
CA2073166A1 (en) Process to correct and optimize the composition of a feed
CA2224896A1 (en) Purified heat-coagulated potato protein for use in animal feed
CA2178592A1 (en) Long-acting injection suspensions and a process for their preparation
CA2186423A1 (en) Protein which induces interferon-gamma production by immunocompetent cell
CA2101075A1 (en) Peptides for the treatment of conditions caused by herpes virus infections
CS316491A3 (en) Derivatives of amino acids, process of their preparation and pharmaceuticals based thereon
CA2105282A1 (en) Preparation of factor ix
IE900285L (en) Peptides with sulphate ester groups.
CA2102606A1 (en) Compositions for the treatment of chronic fatigue syndrome
DE2416048A1 (en) NEW PEPTIDES WITH BIOLOGICAL EFFECT
CA2021180A1 (en) Process for the preparation of .alpha.-l-aspartyl-l-phenylalanine methyl ester hydrochloride by use of isolated n-formyl-aspartic anhydride
RU96115481A (en) METHOD FOR TREATING DEFORMING OSTEOARTHROSIS OF LARGE JOINTS
CA2242347A1 (en) A method and use of polypeptide in sperm-egg binding to enhance or decrease fertility
IE883545L (en) Peptide structures, immunogens containing them and their uses in the control of fertility

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140218